Deltex Medical (GB:DEMG) has released an update.
Deltex Medical Group PLC reports a stable interim revenue of £1.1 million for the first half of 2024, maintaining the same level as the previous year while substantially reducing overhead costs. The company highlights a 39% decrease in sales and marketing expenses and a promising increase in international orders for their new TrueVue monitor. Additionally, the appointment of Natalie Wettler as Chief Operating Officer aims to bolster the Group’s operational management and drive further sales internationally.
For further insights into GB:DEMG stock, check out TipRanks’ Stock Analysis page.